---
document_datetime: 2025-11-23 08:09:58
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/avandamet.html
document_name: avandamet.html
version: success
processing_time: 0.1055264
conversion_datetime: 2025-12-26 16:54:15.313278
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Avandamet

[RSS](/en/individual-human-medicine.xml/65528)

##### Expired

This medicine's authorisation has expired

rosiglitazone / metformin

Medicine

Human

Expired

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [More information on Avandamet](#more-information-on-avandamet-457)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

The marketing authorisation for Avandamet ( *rosiglitazone/metformin* ) expired on 20 October 2013 following the decision of the marketing authorisation holder, Smithkline Beecham Ltd., not to apply for a renewal of the marketing authorisation. The marketing authorisation for Avandamet in the European Union (EU) was suspended at that time.

Avandamet was granted marketing authorisation in the European Union (EU) on 20 October 2003 for treatment of type 2 diabetes mellitus treatment of type 2 diabetes mellitus treatment of type 2 diabetes mellitus treatment of type 2 diabetes mellitus.

The marketing authorisation was valid for a 5-year period. It was subsequently renewed for an additional 5-year period on 13 August 2008.

The European Public Assessment Report (EPAR) for Avandamet is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.

Avandamet : EPAR - Summary for the public

English (EN) (752.38 KB - PDF)

**First published:** 18/09/2008

**Last updated:** 08/06/2016

[View](/en/documents/overview/avandamet-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-418)

български (BG) (1.42 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/bg/documents/overview/avandamet-epar-summary-public_bg.pdf)

español (ES) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/es/documents/overview/avandamet-epar-summary-public_es.pdf)

čeština (CS) (1.36 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/cs/documents/overview/avandamet-epar-summary-public_cs.pdf)

dansk (DA) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/da/documents/overview/avandamet-epar-summary-public_da.pdf)

Deutsch (DE) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/de/documents/overview/avandamet-epar-summary-public_de.pdf)

eesti keel (ET) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/et/documents/overview/avandamet-epar-summary-public_et.pdf)

ελληνικά (EL) (1.44 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/el/documents/overview/avandamet-epar-summary-public_el.pdf)

français (FR) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/fr/documents/overview/avandamet-epar-summary-public_fr.pdf)

italiano (IT) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/it/documents/overview/avandamet-epar-summary-public_it.pdf)

latviešu valoda (LV) (1.37 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/lv/documents/overview/avandamet-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (1.28 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/lt/documents/overview/avandamet-epar-summary-public_lt.pdf)

magyar (HU) (1.35 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/hu/documents/overview/avandamet-epar-summary-public_hu.pdf)

Malti (MT) (1.36 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/mt/documents/overview/avandamet-epar-summary-public_mt.pdf)

Nederlands (NL) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/nl/documents/overview/avandamet-epar-summary-public_nl.pdf)

polski (PL) (1.36 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/pl/documents/overview/avandamet-epar-summary-public_pl.pdf)

português (PT) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/pt/documents/overview/avandamet-epar-summary-public_pt.pdf)

română (RO) (1.29 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/ro/documents/overview/avandamet-epar-summary-public_ro.pdf)

slovenčina (SK) (1.36 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/sk/documents/overview/avandamet-epar-summary-public_sk.pdf)

slovenščina (SL) (1.35 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/sl/documents/overview/avandamet-epar-summary-public_sl.pdf)

Suomi (FI) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/fi/documents/overview/avandamet-epar-summary-public_fi.pdf)

svenska (SV) (1.25 MB - PDF)

**First published:**

18/09/2008

**Last updated:**

08/06/2016

[View](/sv/documents/overview/avandamet-epar-summary-public_sv.pdf)

## Product information

Avandamet : EPAR - Product Information

English (EN) (1.85 MB - PDF)

**First published:** 01/09/2009

**Last updated:** 08/06/2016

[View](/en/documents/product-information/avandamet-epar-product-information_en.pdf)

[Other languages (21)](#file-language-dropdown-90)

български (BG) (10.3 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/bg/documents/product-information/avandamet-epar-product-information_bg.pdf)

español (ES) (2.02 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/es/documents/product-information/avandamet-epar-product-information_es.pdf)

čeština (CS) (6.07 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/cs/documents/product-information/avandamet-epar-product-information_cs.pdf)

dansk (DA) (3.29 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/da/documents/product-information/avandamet-epar-product-information_da.pdf)

Deutsch (DE) (3.06 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/de/documents/product-information/avandamet-epar-product-information_de.pdf)

eesti keel (ET) (2.86 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/et/documents/product-information/avandamet-epar-product-information_et.pdf)

ελληνικά (EL) (8.76 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/el/documents/product-information/avandamet-epar-product-information_el.pdf)

français (FR) (3.04 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/fr/documents/product-information/avandamet-epar-product-information_fr.pdf)

italiano (IT) (2.05 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/it/documents/product-information/avandamet-epar-product-information_it.pdf)

latviešu valoda (LV) (6.65 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/lv/documents/product-information/avandamet-epar-product-information_lv.pdf)

lietuvių kalba (LT) (4.2 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/lt/documents/product-information/avandamet-epar-product-information_lt.pdf)

magyar (HU) (5.83 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/hu/documents/product-information/avandamet-epar-product-information_hu.pdf)

Malti (MT) (6.11 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/mt/documents/product-information/avandamet-epar-product-information_mt.pdf)

Nederlands (NL) (3.31 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/nl/documents/product-information/avandamet-epar-product-information_nl.pdf)

polski (PL) (6.46 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/pl/documents/product-information/avandamet-epar-product-information_pl.pdf)

português (PT) (3.63 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/pt/documents/product-information/avandamet-epar-product-information_pt.pdf)

română (RO) (3.79 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/ro/documents/product-information/avandamet-epar-product-information_ro.pdf)

slovenčina (SK) (6.38 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/sk/documents/product-information/avandamet-epar-product-information_sk.pdf)

slovenščina (SL) (3.49 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/sl/documents/product-information/avandamet-epar-product-information_sl.pdf)

Suomi (FI) (2.89 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/fi/documents/product-information/avandamet-epar-product-information_fi.pdf)

svenska (SV) (3.25 MB - PDF)

**First published:**

01/09/2009

**Last updated:**

08/06/2016

[View](/sv/documents/product-information/avandamet-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A20/0063 03/12/2010

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Avandamet : EPAR - All Authorised presentations

English (EN) (725.2 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 08/06/2016

[View](/en/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_en.pdf)

[Other languages (21)](#file-language-dropdown-289)

български (BG) (1.23 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/bg/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_bg.pdf)

español (ES) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/es/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_es.pdf)

čeština (CS) (1.19 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/cs/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/da/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/de/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/et/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (1.25 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/el/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_el.pdf)

français (FR) (1.17 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/fr/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_fr.pdf)

italiano (IT) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/it/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (1.2 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/lv/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (1.18 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/lt/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (1.23 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/hu/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (1.21 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/mt/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/nl/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_nl.pdf)

polski (PL) (1.19 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/pl/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_pl.pdf)

português (PT) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/pt/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_pt.pdf)

română (RO) (1.19 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/ro/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (1.18 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/sk/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (1.18 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/sl/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (1.15 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/fi/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (1.16 MB - PDF)

**First published:**

15/08/2006

**Last updated:**

08/06/2016

[View](/sv/documents/all-authorised-presentations/avandamet-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Avandamet Active substance

- rosiglitazone
- metformin hydrochloride

International non-proprietary name (INN) or common name

- rosiglitazone
- metformin

Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BD03

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

AVANDAMET is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients:

- who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
- in triple oral therapy with sulphonylurea in patients with insufficient glycaemic control despite dual oral therapy with their maximally tolerated dose of metformin and a sulphonylurea (see section 4.4).

## Authorisation details

EMA product number EMEA/H/C/000522 Marketing authorisation holder

SmithKline Beecham Plc

SmithKline Beecham plc

Marketing authorisation issued 20/10/2003 Expiry of marketing authorisation 20/10/2013 Revision 16

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Avandamet : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (1.12 MB - PDF)

**First published:** 01/09/2009

**Last updated:** 08/06/2016

[View](/en/documents/procedural-steps-after/avandamet-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Avandamet-H-C-522-A20-0063: EPAR - Assessment Report

Adopted

English (EN) (1.52 MB - PDF)

**First published:** 17/01/2011

**Last updated:** 08/06/2016

[View](/en/documents/variation-report/avandamet-h-c-522-a20-0063-epar-assessment-report_en.pdf)

CHMP post-authorisation summary of positive opinion for Avandamet on 24 January 2008

Adopted

Reference Number: EMEA/CHMP/42782/2008

English (EN) (490.91 KB - PDF)

**First published:** 24/01/2008

**Last updated:** 09/06/2016

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-avandamet-24-january-2008_en.pdf)

Avandamet-H-C-522-II-17 : EPAR - Scientific Discussion - Variation

Adopted

English (EN) (897.2 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 08/06/2016

[View](/en/documents/scientific-discussion-variation/avandamet-h-c-522-ii-17-epar-scientific-discussion-variation_en.pdf)

## Initial marketing authorisation documents

Avandamet : EPAR - Procedural steps taken before authorisation

English (EN) (744.05 KB - PDF)

**First published:** 15/08/2006

**Last updated:** 08/06/2016

[View](/en/documents/procedural-steps/avandamet-epar-procedural-steps-taken-authorisation_en.pdf)

Avandamet : EPAR - Scientific Discussion

English (EN) (1 MB - PDF)

**First published:** 15/08/2006

**Last updated:** 08/06/2016

[View](/en/documents/scientific-discussion/avandamet-epar-scientific-discussion_en.pdf)

#### More information on Avandamet

- [Rosiglitazone: a European regulatory perspective](http://www.springerlink.com/content/45455t1548227052/)

**This page was last updated on** 08/06/2016

## Share this page

[Back to top](#main-content)